Eventually, continued investigation will yield valuable insights about cell biology, transcriptional survival mechanisms and potentially the generation of specific inhibitors of SETDB1 and SETDB2 to trial alongside current therapies (such as immuno- and targeted therapy) to maximise the efficacy, length and clinical benefit of modern cancer treatments. Here, SETDB2 is linked to cancer.